| Date |
Research Question / Title |
Unique ID |
Research Team |
|
April 4, 2020
|
What is the evidence for early implementation of field hospitals for COVID-19?
|
EOC040203 RR
|
EOC
|
|
April 7, 2020
|
What is the prevalence of sore throat as a symptom of COVID-19?
|
EOC040201 RR
|
EOC
|
|
April 11, 2020
|
Is the IgM or IgG immune response protective?
|
LAB040803 RR
|
Laboratory
|
|
April 14, 2020
|
What decision support or communication materials are available for helping LTC directors discuss care options with resdients' family members?
|
LTC040801 RR
|
Long Term Care
|
|
April 15, 2020
|
At what time in the disease timeline of COVID-19 do antibodies develop?
|
LAB041402 RR
|
Laboratory
|
|
April 15, 2020
|
How well does the presence and level of antibodies predict the presence or absence of the disease?
|
LAB041401 RR
|
Laboratory
|
|
April 17, 2020
|
What distinguishes COVID-19 from influenza-like illnesses?
|
PPE041701 RR
|
Personal Protective Equipment
|
|
April 17, 2020
|
How well does the presence and level of antibodies predict the clinical course of disease?
|
LAB041501 RR
|
Laboratory
|
|
April 27, 2020
|
What is the best evidence to guide the sequence or priority of re-opening each type of healthcare service and how have the closures impacted patients?
|
EOC042202 RR
|
EOC
|
|
April 27, 2020
|
What are the classification levels for disease severity of COVID-19 and how should each level be treated?
|
EOC042201 RR
|
EOC
|
|
April 29, 2020
|
How can LTC facilities prepare for a pandemic?
|
LTC042201 RR
|
Long Term Care
|
|
April 30, 2020
|
How is "compassionate visit" defined and operationalized in the context of an infectious outbreak or pandemic?
|
LTC042402 RR
|
Long Term Care
|
|
May 7, 2020
|
What are best practices for engaging family care providers during a pandemic?
|
LTC042401 RR
|
Long Term Care
|
|
May 8, 2020
|
What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update]
|
LAB040701v2 RR
|
Laboratory
|
|
May 11, 2020
|
What percentage of COVID-19 patients have hyposmia or anosmia?
|
EOC033102 RR
|
EOC
|
|
May 19, 2020
|
What are the risk factors for severity and death associated with COVID-19?
|
EPM050901 RR
|
Epidemiology & Modelling
|
|
May 19, 2020
|
Risk estimates for clinical factors predicting severity and/ or mortality associated with COVID-19
|
EPM050901 RR Table
|
Epidemiology & Modelling
|
|
May 19, 2020
|
What is the relationship between antibody development and viral shedding and infectiousness? [Update]
|
LAB041601v2 RR
|
Laboratory
|
|
May 22, 2020
|
In similar jurisdictions experiencing the COVID-19 pandemic, what is the proportion of patients receiving non-invasive ventilation versus those receiving intermittent mandatory ventilation?
|
EOC052102 RR
|
EOC
|
|
May 25, 2020
|
What are the fatality rates associated with COVID-19 for ICU, hospitalized, and patients discharged from ICU to general wards?
|
EPM052101 RR
|
Epidemiology & Modelling
|
